PRECIGEN, INC. Payments to Noncontrolling Interests
PRECIGEN, INC. (PGEN) reported Payments to Noncontrolling Interests of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaymentsToMinorityShareholders · last filed 2020-03-02
- PRECIGEN, INC. payments to noncontrolling interests for fiscal 2019 was $0.00.
- PRECIGEN, INC. payments to noncontrolling interests for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- PRECIGEN, INC. payments to noncontrolling interests for fiscal 2017 was $913.00K.
| Period end | Payments to Noncontrolling Interests 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-02 |
| 2017-12-31 | $913.00K 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |